Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform
June 08 2020 - 7:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological diseases, today announced multiple
presentations across its rare neurological disease platform are
available on the 2020 American Academy of Neurology (AAN) Science
Highlights platform. The presentations were originally slated for
discussion at the AAN 72nd Annual Meeting scheduled for April
25-May 1, which was cancelled due to the COVID-19 pandemic. The
abstracts were also published in the online supplement to
Neurology.
The presentations available on the AAN Science Highlights online
platform include the following:
Presentations on OV101 (gaboxadol) in Neurodevelopmental
Disorders:
Title: The adaptation and utility of the
Clinical Global Impression scale for studying treatment outcomes in
neurodevelopmental conditions Topic: Child
Neurology and Developmental Neurology
Title: The pivotal Phase 3 NEPTUNE trial
investigating OV101 (gaboxadol) in Angelman syndrome: study
overview and rationale Topic: Child Neurology and
Developmental Neurology
Title: Evidence of pharmacodynamic tolerance
during repeated daily OV101 (gaboxadol) exposure in individuals
with Angelman syndrome Topic: Child Neurology and
Developmental Neurology
Title: Physiologically based pharmacokinetic
modeling (PBPK) for OV101 (gaboxadol) exposure in children with
Angelman syndrome Topic: Child Neurology and
Developmental Neurology
Title: Caregiver insight on the core domains in
Angelman syndrome Topic: Child Neurology and
Developmental Neurology
Title: Quality of life in adolescent and adult
individuals with Angelman syndrome: Baseline results from the Phase
2 STARS study Topic: Child Neurology and
Developmental Neurology
Title: Concomitant medication in adolescent and
adult individuals with Angelman syndrome: Baseline results from the
Phase 2 STARS study Topic: Child Neurology and
Developmental Neurology
Title: The Phase 2a ROCKET trial investigating
OV101 (gaboxadol) in adolescents and young adults with Fragile X
syndrome Topic: Child Neurology and Developmental
Neurology
Presentations on OV935/TAK935 (soticlestat) in Rare
Developmental and Epileptic Encephalopathies (DEE):
Title: Initial data from the ongoing ENDYMION
open-label extension trial of soticlestat (TAK-935/OV935) in
participants with developmental and/or epileptic encephalopathies
(DEE) Topic: Epilepsy/Clinical Neurophysiology
(EEG)
Title: A phase 1b/2a study of soticlestat
(TAK-935/OV935) as adjunctive therapy in patients with
developmental and epileptic encephalopathies
Topic: Epilepsy/Clinical Neurophysiology
(EEG)
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company using its
BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The Company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing
OV935/TAK935 (soticlestat) in collaboration with Takeda
Pharmaceutical Company Limited for the potential treatment of rare
developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit
http://www.ovidrx.com/.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan,
Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman 1AB katie@1abmedia.com
(919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2024 to May 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From May 2023 to May 2024